TZDs are known to improve systemic insulin sensitivity in animal models of obesity-linked insulin resistance and diabetes by enhancing glucose disposal in skeletal muscle and suppressing gluconeogenesis in the liver [32]. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.